Colorectal cancer – A silent killer

Colorectal cancer awareness month
It's important to detect and screen for colorectal cancer at early stage. With newer therapies and drugs, colorectal cancer can be treated at early stage.

Share This Post

Colorectal cancer, a type of cancer that can remain silent, can have no symptoms at an early stage, but it is the third leading cause of cancer-related deaths in the United States. March is colorectal cancer month, do you have enough knowledge about colorectal cancer?

Colorectal cancer does not have any symptoms in the early stage, and once found, most of them are in advanced stage. However, screening can help detect cancer early, and may involve stool tests, colonoscopy, or other surgeries. Non-risk ordinary people should also start colorectal cancer screening at the age of 50, but people with higher risk factors, such as Crohn’s disease history, inflammatory bowel disease, or those with certain genetic markers, should start screening earlier check. Although colorectal cancer kills about 50,000 Americans each year, you can still reduce your risk of cancer. Increasing physical activity, limiting alcohol intake, and avoiding smoking have been shown to completely reduce the risk of colorectal cancer. 

Colorectal cancer is highly treatable, and the earlier it is detected, the greater the chance of survival. So, don’t ignore screening. This colorectal cancer month, should you do something?

Subscribe To Our Newsletter

Get updates and never miss a blog from Cancerfax

More To Explore

Adagrasib with cetuximab has received accelerated approval by FDA for KRAS G12C-mutated colorectal cancer
Colon cancer

Adagrasib with cetuximab has received accelerated approval by FDA for KRAS G12C-mutated colorectal cancer

The FDA has granted accelerated approval to Adagrasib combined with Cetuximab for treating KRAS G12C-mutated colorectal cancer. This approval is based on promising clinical trial results showing enhanced efficacy of the drug duo. Adagrasib, a KRAS inhibitor, and Cetuximab, an EGFR inhibitor, together target the cancer more effectively, offering new hope for patients with this specific genetic mutation, aiming to improve survival rates and treatment outcomes.

Pembrolizumab with chemotherapy is approved by the USFDA for primary advanced or recurrent endometrial carcinoma
Endometrial cancer

Pembrolizumab with chemotherapy is approved by the USFDA for primary advanced or recurrent endometrial carcinoma

The USFDA has approved Pembrolizumab combined with chemotherapy for treating primary advanced or recurrent endometrial carcinoma. This approval is based on clinical trial data showing significant improvements in patient outcomes. Pembrolizumab, an immune checkpoint inhibitor, works by enhancing the body’s immune response against cancer cells. This combination therapy offers a new and promising treatment option for patients facing this challenging and often aggressive cancer.

Need help? Our team is ready to assist you.

We wish a speedy recovery of your dear and near one.

Start chat
We Are Online! Chat With Us!
Scan the code
Hello,

Welcome to CancerFax !

CancerFax is a pioneering platform dedicated to connecting individuals facing advanced-stage cancer with groundbreaking cell therapies like CAR T-Cell therapy, TIL therapy, and clinical trials worldwide.

Let us know what we can do for you.

1) Cancer treatment abroad?
2) CAR T-Cell therapy
3) Cancer vaccine
4) Online video consultation
5) Proton therapy